ABT Stock Recent News
ABT LATEST HEADLINES
Despite trade policy challenges, Abbott's global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains.
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments.
Investing in excellent dividend stocks can be a great strategy to mitigate risk and boost long-term returns. Companies that can dispense regular payouts to their shareholders -- especially those that have done so for a long time -- generally have stable and steadily growing businesses that can perform relatively well even amid downturns.
A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser subsidiary Mead Johnson for premature babies can cause a fatal intestinal illness, as the companies face hundreds of lawsuits over the claims.
The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutes The test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025 ABBOTT PARK, Ill., and IRVINE, Calif.
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%.
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers.
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?